IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Attv Dkt. 1579-863

C# M#

HELLINGA et al.

Serial No. 10/686,529

October 16, 200\$ Filed:

BIOSENSOR Title:

Examiner: R.A. Zeman

T.C. / Art Unit:

1645

Date: October 19, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO NOTICE TO COMPLY

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ Correspondence Address Indication Form Attached.

OCT 1 9 200

Fees are attached as calculated below:

Total effective claims after amendment 22 minus highest number

previously paid for (at least 20) = x \$50.00 22 \$0.00 (1202)/\$0.00 (2202) \$

Independent claims after amendment 4 minus highest number

previously paid for x \$200.00 4 (at least 3) =0 \$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add

\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this

paper and attachment(s) One Month Extension \$120.00 (1251)/\$60.00 (2251)

Two Month Extensions \$450.00 (1252)/\$225.00 (2252)

Three Month Extensions \$1020.00 (1253/\$510.00 (2253)

Four Month Extensions \$1590.00 (1254/\$795.00 (2254) \$

Terminal disclaimer enclosed, add

\$130.00 (1814)/\$65.00 (2814) \$

Applicant claims "small entity" status. Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806) \$

Assignment Recording Fee \$40.00 (8021) \$

\$ Other: COPY OF NOTICE TO COMPLY

> **TOTAL FEE ENCLOSED \$** 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

GRT:ap

NIXON & VANDERHYE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature:

A lication No.: 10/686,529

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
Applicant must file the items indicated below within the time period set the Office action to what the Notice is attached to avoid abandonment under 35 U.S.C. 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a □Sequence Listing□ as required by 37 C.F.R. 1.821(c).
3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the Sequence Listing is not the same as the computer readable from of the □Sequence Listing□ as required by 37 C.F.R. 1.821(e).
7. Other: the 3 sequences present in Figure 2 are not readily identifiable. The amendment to the specification does not which sequence constitutes a given SEQ ID NO.
Applicant Must Provide:
An initial or <u>substitute</u> computer readable form (CRF) copy of the Sequence Listing
An initial or <u>substitute</u> paper copy of the □Sequence Listing, as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentle Software Program Support

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY